Our aim is to study the termination of disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) and the causes of withdrawal. We have reviewed the prospective protocols of patients with PsA and collected the data on treatments and causes of withdrawal. Fifty-four out of 96 patients (48 male and 48 female) have undergone one or more courses of DMARD (n = 109). The life-table analysis shows a survival rate of 6 months for gold sodium thiomalate (GOLD) and sulphasalazine (SSZ), and 16 months for methotrexate (MTX). The Mantel-Haenszel test finds statistical differences between GOLD and MTX. There are no differences between MTX and SSZ or between GOLD and SSZ. The absence of differences for MTX and SSZ could be explained by the heterogeneity of both groups. The most common cause of withdrawal for GOLD and SSZ are adverse effects.
PSORIATIC arthritis (PsA) is an inflammatory arthritis associated with psoriasis that is usually seronegative for rheumatoid factor [1] . Unlike rheumatoid arthritis, PsA is considered a mild form of arthritis and most patients respond to non-steroidal anti-inflammatory drugs [2] . When this treatment fails, an attempt to control inflammation with intra-articular steroids is usually effective. However, a remaining percentage of patients need to be treated with one or more disease-modifying anti-rheumatic drugs (DMARDs).
A difficult question arises when the clinician has to choose among the different DMARDs. Several studies have tried to solve this problem. Gold [3] , penicillamine [4] , antimalarials [5, 6] , methotrexate [7, 8] , sulphasalazine [9, 10] , azathioprine [11] , retinoids [12, 13] , cyclosporin A [14] and colchicine [15] have been included in several studies to determine their efficacy and toxicity. In addition, PsA introduces two difficulties not present in other diseases like rheumatoid arthritis: (a) the heterogeneity of the patients included, because of the clinical forms of PsA, makes it difficult to establish comparisons among groups and (b) a high loss in the follow-up is present in all these studies, although it appears to be at random [16] .
We have studied the termination of long-term treatments of PsA with DMARDs and the causes of withdrawal of the drugs by means of a life-table analysis. The duration of drug therapy is determined by the balance of the severity of the disease and the efficacy and toxicity of the drug. So, life-table analyses are an indirect method to measure the efficacy and toxicity of the drugs compared [17] . 
PATIENTS AND METHODS
Our service has a standardized protocol that includes information about clinical history, physical examination, laboratory data, radiology and treatment of every patient with PsA. We have entered prospectively into the protocol all the patients diagnosed with PsA in our service since 1984. They are seen at 3 month intervals.
We have reviewed the protocols and included all the patients in the study, except those whose follow-up was missing. We have collected the data on the patients (sex and age) and on the PsA (duration and functional class [18] ). The clinical forms recorded are monoarticular, oligoarticular and symmetrical or asymmetrical polyarticular. We have not considered axial involvement as a distinct clinical form.
We have gathered information about the DMARD treatments undergone by every patient: number and dose of DMARDs taken, duration of treatment and causes of withdrawal (toxicity, inefficacy, clinical remission and personal reasons). Patients were not randomly allocated to the therapies; indication for drug therapy and causes of withdrawal depended on the criteria of every doctor. We have considered as inefficacy the persistence of actively inflamed joints after 3-4 months of therapy. Similarly, clinical remission is the absence of articular signs or symptoms. We have included only courses initiated by the authors in the study period. We have not monitored the severity of skin disease.
All patients with DMARDs were taking concurrent non-steroidal anti-inflammatory drug treatment and some of them also took systemic corticosteroids (dose <7.5mg of prednisone or equivalent). The administration of intra-articular steroids was not a cause of exclusion from the study. We used to recommend the patients who started on methotrexate to abstain Figure 1 shows the Kaplan-Meier life table for GOLD, MTX and SSZ.
The Mantel-Haenszel test finds statistical differences (P < 0.01) between GOLD and MTX. There are no differences between MTX and SSZ or between GOLD and SSZ.
The causes of termination of DMARDs are presented in Table III . While the most common cause of withdrawal for GOLD and SSZ are adverse effects, only one of the 27 patients who took MTX stopped it for adverse effects. We had two cases of withdrawal because of clinical remission: one in treatment with MTX and the other with SSZ.
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CONCLUSIONS
The results of this life-table analysis show a survival rate of 16 months for MTX, and 6 months for GOLD and SSZ. This could give the idea that MTX has fewer terminations than GOLD or SSZ. It seems to be true for GOLD, but concerning SSZ, this impression is not confirmed by the Mantel-Haenszel test; there are no statistical differences between the survival times of MTX and SSZ. The answer to this result may be in the slope of the Kaplan-Meier life table (Fig. 1) . Whereas for MTX the terminations are gradual, for SSZ there is initially a great withdrawal, followed by a long period of plateau; both drugs have similar survival rates after 30 months. According to our results, we do not find differences between the median survival time for MTX and SSZ.
When survival studies in rheumatoid arthritis include MTX [19, 20] , the survival time is superior to the others. Does the same occur with PsA? Our results suggest that it does not. If we analyse the composition of the treatment groups (Table IV) , we find substantial differences among the clinical forms of PsA in the patients included. The group treated with SSZ has a higher proportion of oligoarticular forms opposite the higher prevalence of polyarticular forms in the MTX group. This difference could be explained by our trend of treating polyarticular forms with MTX, as we do in rheumatoid arthritis. The heterogeneity of both treatment groups (because of the poor prognosis of polyarticular forms) could explain the absence of differences in the survival rates of MTX and SSZ, and the discordance with the results of similar studies in rheumatoid arthritis. On the other hand, a higher dose of SSZ, some authors use 3 or 4 g/day, could possibly have achieved better results than ours.
The most common cause of withdrawal for GOLD and SSZ are adverse effects. This is reflected in the Kaplan-Meier life table by a great discontinuation in the beginning of treatment. Only one of the 27 patients who took MTX stopped it for adverse effects. We had no case of severe toxicity. In our study, MTX seems to be the safest DMARD. These results do not agree with those published recently by Abu-Shakra et al. [21] : MTX treatment was withdrawn in 8 out of 38 patients due to side-effects. The reason for the discordance may be the lower weekly dose of MTX prescribed in our study.
We had two cases of withdrawal because of clinical remission: one in treatment with MTX and the other with SSZ. There were 22 patients who stopped the treatments because of inefficacy; only four of them were taking MTX.
To conclude, MTX and SSZ are the DMARDs with the best survival rate in PsA, and MTX has a very low toxicity. In the light of these results, and despite the limitations of this study due to the small number of patients included, we think that MTX ought to be the first-choice DMARD in PsA.
